

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Stephen Kawai	02/27/2013
Francois Bilodeau	02/22/2013
Christiane Yoakim	02/07/2013
Murray D. Bailey	02/20/2013
Rebekah Carson	02/11/2013
Lee Fader	02/09/2013
Sebastien Morin	02/07/2013
Carl Thibeault	02/11/2013
Bruno Simoneau	02/08/2013
Simon Surprenant	02/07/2013
Steven R. Laplante	02/07/2013
Youla S. Tsantrizos	02/22/2013

RECEIVING PARTY DATA

Name:	Gilead Sciences, Inc.
Street Address:	333 Lakeside Drive
City:	Foster City
State/Country:	CALIFORNIA
Postal Code:	94404

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	13683706

CORRESPONDENCE DATA

Fax Number: 6505225575
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Phone: 6505224284
 Email: Lisa.Naranjo@gilead.com

CH \$40.00 13683706

Correspondent Name:	Gilead Sciences, Inc.
Address Line 1:	333 Lakeside Drive
Address Line 4:	Foster City, CALIFORNIA 94404

ATTORNEY DOCKET NUMBER:	BI13-157US3C
-------------------------	--------------

NAME OF SUBMITTER:	Mary J. Edwards
--------------------	-----------------

Total Attachments: 7

source=BI13-157US3C_Signed_Assignment#page1.tif
source=BI13-157US3C_Signed_Assignment#page2.tif
source=BI13-157US3C_Signed_Assignment#page3.tif
source=BI13-157US3C_Signed_Assignment#page4.tif
source=BI13-157US3C_Signed_Assignment#page5.tif
source=BI13-157US3C_Signed_Assignment#page6.tif
source=BI13-157US3C_Signed_Assignment#page7.tif

ASSIGNMENT BY INVENTORS

THIS ASSIGNMENT, made by Christiane Yoakim; Murray D. Bailey; Francois Bilodeau; Rebekah Carson; Lee Fader; Stephen Kawai; Sebastien Morin; Carl Thibeault; Bruno Simoneau; Simon Surprenant; Youla S. Tsantrizos; and Steven R. Laplante (hereinafter referred to as Assignors), residing at 2100 Cunard Street, Laval, Quebec H7S 2G5, CANADA; 2100 Cunard Street, Laval, Quebec H7S 2G5, CANADA; 2100 Cunard Street, Laval, Quebec H7S 2G5, CANADA; 2100 Cunard Street, Laval, Quebec H7S 2G5, CANADA; 2100 Cunard Street, Laval, Quebec H7S 2G5, CANADA; 2100 Cunard Street, Laval, Quebec H7S 2G5, CANADA; 2100 Cunard Street, Laval, Quebec H7S 2G5, CANADA; 2100 Cunard Street, Laval, Quebec H7S 2G5, CANADA; 2100 Cunard Street, Laval, Quebec H7S 2G5, CANADA; 2100 Cunard Street, Laval, Quebec H7S 2G5, CANADA; 2100 Cunard Street, Laval, Quebec H7S 2G5, CANADA; and 2100 Cunard Street, Laval, Quebec H7S 2G5, CANADA, respectively;

WHEREAS, Assignors have invented certain new and useful improvements in INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION, set forth in a Patent application for Letters Patent of the United States, already filed on November 21, 2012 as U.S. Application No. 13/683,706; and

WHEREAS, Gilead Sciences, Inc., a Corporation organized under and pursuant to the laws of Delaware having its principal place of business at 333 Lakeside Drive, Foster City, California 94404 (hereinafter referred to as Assignee), is desirous of acquiring the entire right, title and interest in and to said inventions and said Application for Letters Patent of the United States, and in and to any Letters Patent of the United States to be obtained therefore and thereon.

NOW, THEREFORE, to all whom it may concern, be it known that for good and sufficient consideration, the receipt of which is hereby acknowledged, Assignors have sold, assigned, transferred and set over, and by these presents do sell, assign, transfer and set over, unto Assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned inventions

and application for Letters Patent, and in and to any and all direct and indirect divisions, continuations, continuations-in-part, and continuing applications of said application, and any and all Letters Patent in the United States and all foreign countries which may be granted therefore and thereon, and reissues, reexaminations and extensions of said Letters Patent, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee, for its own use and benefit and the use and benefit of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent may be granted and/or extended, as fully and entirely as the same would have been held and enjoyed by Assignors, had this sale and assignment not been made.

AND for the same consideration, Assignors hereby represent and warrant to Assignee, its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, except for any rights, titles and/or interests that have arisen to Assignee under law or that have already been transferred to Assignee, Assignors are the sole and lawful owners of the entire right, title and interest in and to the said inventions and application for Letters Patent above-mentioned, and that the same are unencumbered and that Assignors have good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, Assignors hereby covenant and agree to and with Assignee, its successors, legal representatives and assigns, that Assignors will sign all papers and documents, take all lawful oaths and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of any Letters Patent and applications for Letters Patent for said inventions, without charge to Assignee, its successors, legal representatives and assigns, whenever counsel of Assignee, or counsel of its successors, legal representatives and assigns, shall advise: that any proceeding in connection with said inventions, or said Patent application for Letters Patent, or any proceeding in connection with any Letters Patent or applications for Letters Patent for said inventions including but not limited to interference proceedings, is lawful and desirable; or, that any division, continuation or continuation-in-part of any application for Letters Patent, or any reissue, reexamination or extension of any Letters Patent, to be obtained thereon, is lawful and desirable.

AND Assignors acknowledge an obligation of assignment of this invention to Assignee at the time the invention was made.

Date: _____ Signature: _____
Christiane Yeakim

Date: _____ Signature: _____
Murray D. Bailey

Date: _____ Signature: _____
Francois Bilodeau

Date: _____ Signature: _____
Rebekah Carson

Date: _____ Signature: _____
Lee Fader

Date: 27 Feb 2013 Signature: _____
Stephen Kawai

Date: _____ Signature: _____
Sebastien Morin

Date: _____ Signature: _____
Carl Thibeault

AND Assignors acknowledge an obligation of assignment of this invention to Assignee at the time the invention was made.

Date: _____ Signature: _____
Christiane Yoakim

Date: _____ Signature: _____
Murray D. Bailey

Date: 22/FEB/2013 Signature: _____
Francis Bilodeau

Date: _____ Signature: _____
Rebekah Carson


Date: _____ Signature: _____
Lee Fader


Date: _____ Signature: _____
Stephen Kawai

Date: _____ Signature: _____
Sebastien Morin


Date: _____ Signature: _____
Carl Thibeault

AND Assignors acknowledge an obligation of assignment of this invention to Assignee at the time the invention was made.

Date: 7 Feb. 2013 Signature: 
Christiane Yoakim


Date: Feb 20, 2013 Signature: 
Murray D. Bailey

Date: _____ Signature: _____
Francois Bilodeau

Date: Feb 11 / 2013 Signature: 
Rebekah Carson

Date: 9 / FEB / 2013 Signature: 
Lee Fader

Date: _____ Signature: _____
Stephery Kawai

Date: 7 Feb. 2013 Signature: 
Sebastien Morin

Date: 11 fevrie 2013 Signature: 
Carl Thibeault

Date: 8 Feb. 2013

Signature: _____

Bruno Simoneau

Date: 7 février
2013

Signature: _____

Simon Surprenant

Date: _____

Signature: _____

Youfa S. Tsantrizos

Date: Feb 7 2013

Signature: _____

Steven R. Laplante

Date: _____ Signature: _____
Bruno Simoneau

Date: _____ Signature: _____
Simon Surprenant

Date: Feb 22, 2013 Signature: _____
Youfa S. Tسانtrizos

Date: _____ Signature: _____
Steven R. Laplante